Innovation Pharmaceuticals Inc (IPIX)

[sunspotter]

“The Phase 2 COVID-19 clinical trial data as of the date of this Form 10-Q has yet to have undergone full data analysis and review as biostatistics data is still forthcoming from its vendor. The Company expects this process to be completed during February and plans to subsequently report findings.”

Mangled English and I suspect there is a “not” missing before “forthcoming”.

In any event in the real world of real BioPharmaceutical companies those data relating to secondary endpoints are produced effectively simultaneously with the data related to the primary.

That’s simply the way statistical analysis packages work.

Either this statement is a lie, or IPIX has not received this data because it has not paid the “vendor”.